Recro Pharma PE Ratio 2014-2020 | REPH

Current and historical p/e ratio for Recro Pharma (REPH) from 2014 to 2020. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Recro Pharma PE ratio as of June 05, 2020 is 0.00.

Recro Pharma, Inc. is a clinical stage specialty pharmaceutical company. It develops non-opioid therapeutics for the treatment of pain in the post-operative setting. The company is developing intranasal formulation of Dexmedetomidine (Dex) for the treatment of post-operative pain and cancer breakthrough pain; sublingual formulation of Dex for the treatment of chronic pain; and Fadolmidine (Fado), a product candidate to treat post-operative pain and neuropathic pain. Recro Pharma, Inc. is based in Malvern, Pennsylvania.

We Need Your Support!

Backlinks from other websites are the lifeblood of our site and a primary source of new traffic.

If you use our chart images on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. We have provided a few examples below that you can copy and paste to your site:

We Need Your Support!

Backlinks from other websites are the lifeblood of our site and a primary source of new traffic.

If you use our datasets on your site or blog, we ask that you provide attribution via a "dofollow" link back to this page. We have provided a few examples below that you can copy and paste to your site: